Relmada Therapeutics, Inc. RLMD

3.83 0.02 0.52% as of 25 Sep
Market cap
$406.4M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Jun '18 Dec '18 Jun '19 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
0.46 0.46 3.83 80.22 9.37 14.83 12.26 8.00 4.45 14.62
Net Debt/EBITDA
(0.07) (0.06) 0.76 7.71 1.92 1.69 0.92 0.93 0.54 1.57
Debt/Equity
(0.48) (0.48) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
442.21% 162.54% (1,649.19%) (24.34%) (53.74%) (80.14%) (90.07%) (87.51%) (132.33%) (94.05%)
ROA
(304.53%) (293.98%) (261.05%) (23.56%) (50.53%) (73.64%) (83.48%) (78.89%) (111.57%) (82.08%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
284.06% 284.06% (234.50%) (12.99%) (56.37%) (60.39%) (111.85%) (115.80%) (225.27%) (65.54%)
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — — —
Free Cash Flow per Share
(1.92) (1.91) (1.66) (1.31) (1.78) (5.23) (3.50) (1.72) (1.72) (1.16)
Book value per Share
(1.76) (1.76) 1.21 12.52 6.77 11.87 4.74 2.84 1.18 2.19
Free Cash Flow
(6.01) (6.00) (10.50) (12.09) (27.81) (91.87) (103.80) (51.66) (51.76) (45.79)
Other line items

Show all line items

Columns are period end dates